scholarly article | Q13442814 |
P356 | DOI | 10.3109/00498254.2014.897011 |
P698 | PubMed publication ID | 24588343 |
P50 | author | Heather Eng | Q99552335 |
P2093 | author name string | Amit S Kalgutkar | |
Raman Sharma | |||
Margaret S Landis | |||
Benjamin D Stevens | |||
Thomas S McDonald | |||
P2860 | cites work | Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 | Q24563957 |
Mass spectrometry of peptides and proteins | Q28235966 | ||
The Physiology of Glucagon-like Peptide 1 | Q28373115 | ||
Peptide sequence analysis | Q33231175 | ||
Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides | Q33788748 | ||
Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy | Q34786386 | ||
Cardiovascular biology of the incretin system | Q36484283 | ||
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance | Q36750350 | ||
Therapy in the early stage: incretins | Q36783865 | ||
Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides | Q37212333 | ||
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies | Q37735524 | ||
GLP-1 based therapies: differential effects on fasting and postprandial glucose | Q37974712 | ||
GLP-1 receptor agonists: a clinical perspective on cardiovascular effects | Q38002008 | ||
Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis | Q42022343 | ||
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 | ||
Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. | Q42479294 | ||
GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes | Q42964903 | ||
In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes | Q44317184 | ||
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy | Q45020436 | ||
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy | Q46604606 | ||
GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide | Q46637836 | ||
Glucagon-like peptide-1(7–37) has a larger volume of distribution than glucagon-like peptide-1(7–36)amide in dogs and is degraded more quickly in vitro by dog plasma | Q58449077 | ||
Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects | Q58449089 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | pharmacokinetics | Q323936 |
P304 | page(s) | 842-848 | |
P577 | publication date | 2014-03-04 | |
P1433 | published in | Xenobiotica | Q1360678 |
P1476 | title | Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs | |
P478 | volume | 44 |
Search more.